Antiresorptive Effects of Phytoestrogen Supplements Compared with Estradiol or Risedronate in Postmenopausal Women Using 41Ca Methodology
Open Access
- 1 October 2009
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (10), 3798-3805
- https://doi.org/10.1210/jc.2009-0332
Abstract
Introduction: Reduction of ovarian estrogen secretion at menopause increases net bone resorption and leads to bone loss. Isoflavones have been reported to protect bone from estrogen deficiency, but their modest effects on bone resorption have been difficult to measure with traditional analytical methods. Methods: In this randomized-order, crossover, blinded trial in 11 healthy postmenopausal women, we compared four commercial sources of isoflavones from soy cotyledon, soy germ, kudzu, and red clover and a positive control of oral 1 mg estradiol combined with 2.5 mg medroxyprogesterone or 5 mg/d oral risedronate (Actonel®) for their antiresorptive effects on bone using novel 41Ca methodology. Results: Risedronate and estrogen plus progesterone decreased net bone resorption measured by urinary 41Ca by 22 and 24%, respectively (P < 0.0001). Despite serum isoflavone profiles indicating bioavailability of the phytoestrogens, only soy isoflavones from the cotyledon and germ significantly decreased net bone resorption by 9% (P = 0.0002) and 5% (P = 0.03), respectively. Calcium absorption and biochemical markers of bone turnover were not influenced by interventions. Conclusions: Dietary supplements containing genistein-like isoflavones demonstrated a significant but modest ability to suppress net bone resorption in postmenopausal women at the doses supplied in this study over a 50-d intervention period. Commercial phytoestogen supplement preparations have modest ability to reduce bone resorption in postmenopausal women compared to traditional therapies.Keywords
This publication has 31 references indexed in Scilit:
- Soy isoflavone intake increases bone mineral density in the spine of menopausal women: Meta-analysis of randomized controlled trialsClinical Nutrition, 2008
- Evaluation of 41Calcium as a New Approach to Assess Changes in Bone Metabolism: Effect of a Bisphosphonate Intervention in Postmenopausal Women With Low Bone MassJournal of Bone and Mineral Research, 2007
- Soy Isoflavones Do Not Affect Bone Resorption in Postmenopausal Women: A Dose-Response Study Using a Novel Approach with 41CaJournal of Clinical Endocrinology & Metabolism, 2006
- Measuring calcium absorption and utilization in humansCurrent Opinion in Clinical Nutrition and Metabolic Care, 2006
- Soy Isoflavones and Bone Health: A Double-Edged Sword?Journal of Natural Products, 2005
- Estrogenic agonism and antagonism of the soy isoflavone genistein in uterus, bone and lymphopoiesis in miceAPMIS, 2005
- The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled studyBone, 2005
- Identification of Puerarin and Its Metabolites in Rats by Liquid Chromatography−Tandem Mass SpectrometryJournal of Agricultural and Food Chemistry, 2004
- Effects of Genistein and Hormone-Replacement Therapy on Bone Loss in Early Postmenopausal Women: A Randomized Double-Blind Placebo-Controlled StudyJournal of Bone and Mineral Research, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002